In order to attempt to identify cancer associated genetic alterations which predict sensitivity to PDK inhibition we decided to study cell lines harboring oncogenic mutations in genes which are linked with a highly glycolytic phenotype (KRAS) or have been previously reported to demonstrate sensitivity to PDK-1 knock-down (BRAF) [24, 25]. The gene discussed is PDK1; the disease is cancer.